Arginase deficiency is a rare autosomal recessive metabolic disorder that disrupts the final step of the urea cycle, impairing the conversion of arginine into urea and ornithine. In affected ...

For people living with arginase deficiency, a condition without an effective treatment, it is good news that a new therapy that offers dramatic improvement for patients with the condition has been ...

ERYTECH Pharma, a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research ...

Marketresearch.biz reports that the Arginase Deficiency Market size is expected to be worth around USD 152.3 Mn by 2032 from USD 102 Mn in 2022, growing at a CAGR of 4.2% during the forecast period ...

AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit ...

AUSTIN, Texas, Dec. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative ...

AUSTIN, Texas, May 26, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative ...

Pegzilarginase has the Potential to be the First FDA-Approved Treatment to Address the Underlying Cause of ARG1-D, a Devastating Rare Disease with Limited Treatment Options AUSTIN, Texas, May 3, 2021 ...

Marketresearch.biz reports that the Arginase Deficiency Market size is expected to be worth around USD 152.3 Mn by 2032 from USD 102 Mn in 2022, growing at a CAGR of 4.2% during the forecast period ...